Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
Associated Therapies
-

Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients

First Posted Date
2010-04-14
Last Posted Date
2010-11-07
Lead Sponsor
AstraZeneca
Target Recruit Count
16
Registration Number
NCT01103609
Locations
🇬🇧

Research Site, London, United Kingdom

Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2009-12-21
Last Posted Date
2016-05-09
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
3
Registration Number
NCT01036802
Locations
🇺🇸

University of North Carolina, Chapel Hill, North Carolina, United States

Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation

Phase 3
Completed
Conditions
Interventions
First Posted Date
2009-11-03
Last Posted Date
2015-05-20
Lead Sponsor
Texas Cardiac Arrhythmia Research Foundation
Target Recruit Count
1584
Registration Number
NCT01006876
Locations
🇺🇸

St.David's Medical Center, Austin, Texas, United States

Personalized Medicine Interface Tool (PerMIT): Warfarin: A Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy

First Posted Date
2009-10-12
Last Posted Date
2015-06-24
Lead Sponsor
Robert Pendleton
Target Recruit Count
26
Registration Number
NCT00993200
Locations
🇺🇸

University of Utah, Salt Lake City, Utah, United States

BAY59-7939 in Atrial Fibrillation Once Daily (OD)

First Posted Date
2009-09-09
Last Posted Date
2014-12-30
Lead Sponsor
Bayer
Target Recruit Count
102
Registration Number
NCT00973245

BAY59-7939 Japanese in Atrial Fibrillation (2nd)

First Posted Date
2009-09-09
Last Posted Date
2014-12-30
Lead Sponsor
Bayer
Target Recruit Count
100
Registration Number
NCT00973323

Clinical and Economic Implications of Genetic Testing for Warfarin Management

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-08-24
Last Posted Date
2019-11-25
Lead Sponsor
University of Chicago
Target Recruit Count
359
Registration Number
NCT00964353
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2009-08-12
Last Posted Date
2014-07-23
Lead Sponsor
Duke University
Target Recruit Count
145
Registration Number
NCT00957242
Locations
🇺🇸

University of California - Los Angeles, Los Angeles, California, United States

🇺🇸

University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

and more 19 locations

A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation

Phase 2
Completed
Conditions
Interventions
First Posted Date
2009-07-14
Last Posted Date
2011-01-20
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
1280
Registration Number
NCT00938730
© Copyright 2024. All Rights Reserved by MedPath